Login to Your Account



Clinic Roundup


Thursday, June 14, 2012

• Azaya Therapeutics Inc., of San Antonio, Texas, said final results from the Phase I study of its cancer drug, ATI-1123 (liposomal docetaxel), showed 79 percent of heavily pretreated patients received benefit from the compound. The 29 patients enrolled in the study suffered from a variety of solid tumors, including cervical, gastric, melanoma, lung, ovarian, pancreatic, prostate, thyroid and uterine cancers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription